Iron does not cause arrhythmias in the guinea pig model of transfusional iron overload

Comparative Medicine

Volumn 57, Issue 4, 2007, Pages 383-389

  Kaiser, Lana ^a   Davis, John ^a   Patterson, Jon ^b   Boyd, Ryan F ^a   Olivier, N Bari ^b   Bohart, George ^b   Schwartz, Kenneth A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; IRON; IRON DEXTRAN; HEMOSIDERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA THALASSEMIA; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE MODEL; ELECTROCARDIOGRAM; FEMALE; GUINEA PIG; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART WEIGHT; HISTOPATHOLOGY; IRON ABSORPTION; IRON OVERLOAD; LIVER; LIVER WEIGHT; NONHUMAN; RISK FACTOR; TELEMETRY; ANIMAL; BLOOD TRANSFUSION; CHEMISTRY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART MUSCLE; HEART RATE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARRHYTHMIA; BLOOD TRANSFUSION; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; FEMALE; GUINEA PIGS; HEART; HEART RATE; HEMOSIDERIN; IRON OVERLOAD; IRON-DEXTRAN COMPLEX; LIVER; MYOCARDIUM; TELEMETRY;

EID: 34548823505     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adams ET, Schwartz KA. 1993. Iron-induced myocardial and hepatic lysosomal abnormalities in the guinea pig. Toxicol Pathol 21:321-326.
2. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. 2001. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97:3411-3416.
3. Andrews NC, Schmidt PJ. 2007. Iron homeostasis. Annu Rev Physiol 69:69-85.
4. Borgna-Pignatti C, Galanello R. 2003. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: JP Greer, J Foerster, JN Lukens, GM Rodgers, F Paraskevas, BE Glader, editors. Wintrobe's clinical hematology, 11th ed. New York: Lippincott, Williams & Wilkins.
5. Buja LM, Roberts WC. 1971. Iron in the heart: etiology and clinical significance. Am J Med 51:209-221.
6. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP. 2000. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 343:1529-1535.
7. Carthew P, Dorman BM, Edwards RE, Francis JE, Smith AG. 1993. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 69:217-222.
8. Carthew P, Edwards RE, Dorman BM. 1991. Hepatic fibrosis and iron accumulation due to endotoxin-induced haemorrhage in the gerbil. J Comp Pathol 104:303-311.
9. Carthew P, Edwards RE, Smith AG, Dorman B, Francis JE. 1991. Rapid induction of hepatic fibrosis in the gerbil after parenteral administration of iron-dextran complex. Hepatology 13:534-539.
10. Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. 1991. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J 12:224-230.
11. Davis BA, Porter JB. 2000. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood 95:1229-1236.
12. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA. 1980. Longitudinal study of cardiac function in thalassemia major. Annals N Y Acad Sci 344:397-404.
13. Engle MA, Erlandsom M, Smith CH. 1964. Late cardiac complications of chrome, severe, refractory anemia with hemochromatosis. Circulation 30:698-705.
14. Franzoni F, Galetta F, DiMuro C, Buti G, Pentimone F, Santora G. 2004. Heart rate variability and ventricular late potentials in β-thalassemia major. Haematologica 89:233-234.
15. Gehrmann J, Hammer PE, Maguire CT, Wakimoto H, Triedman JK, Berul CI. 2000. Phenotypic screening for heart rate variability in the mouse. Am J Physiol 279:H733-H740.
16. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. 2002. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 139:50-58.
17. Kaiser L, Davis J, Schwartz KA. 2004. Are there problems with the "time-compressed" gerbil model of iron overload? Lab Clin Med 143:130-132.
18. Kaye SB, Owen M. 1978. Cardiac arrhythmias in thalassaemia major: evaluation of chelation therapy using ambulatory monitoring. Br Med J 1:342.
19. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh C-C, Cohen SA, Brown AM. 1999. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Circulation 100:675-683.
20. Laurita KR, Chuck ET, Yang T, Dong W-Q, Kuryshev YA, Brittenham GM, Rosenbaum DS, Brown AM. 2003. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med 142:83-89.
21. Modell B, Berdoukas V. 1984. The clinical approach to thalassaemia. In: Death and survival. London: Grune and Stratton.
22. Modell B, Khan M, Darlison M. 2000. Survival in β-thalassemia major in the UK: data from the UK Thalassaemia Register. Lancet 355:2051-2052.
23. Obejero-Paz CA, Yang T, Dong W-Q, Levy MN, Brittenham GM, Kuryshev YA, Brown AM. 2003. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med 141:121-130.
24. Olivieri NF, Liu PP, Sher GD, Daly PA, Greig PD, McCusker PJ, Collins AF, Francombe WH, Templeton DM, Butany J. 1994. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous β-thalassemia. N Engl J Med 330:1125-1127.
25. Qureshi N, Avasarala K, Foote D, Vichinsky EP. 2005. Utility of Holter electrocardiogram in iron-overloaded hemoglobinopathies. Ann N Y Acad Sci 1054:476-480.
26. Rosenqvist M, Hultcrantz R. 1989. Prevalence of a haemochromatosis among men with clinically significant bradyarrhythmias. Eur Heart J 10:473-478.
27. Schwartz KA, Fisher J, Adams ET. 1993. Morphologic investigations of the guinea pig model of iron overload. Toxicol Pathol 21:311-320.
28. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE. 2002. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol 93:746-751.
29. Short EM, Winkle RA, Billingham ME. 1981. Myocardial involvement in idiopathic hemochromatosis: morphologic and clinical improvement following venesection. Am J Med 70:1275-1279.
30. Strobel JS, Fuisz AR, Epstein AE, Plumb VJ. 1999. Syncope and inducible ventricular fibrillation in a woman with hemochromatosis. J Interv Card Electrophysiol 3:225-229.
31. Weatherall DJ. 2001. The thalassemias. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology, 6th ed. New York: McGraw Hill Medical Publishing.
32. Yang T, Brittenham GM, Dong W-Q, Levy MN, Obejero-Paz CA, Kuryshev YA, Brown AM. 2003. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 142:332-340.
33. Yang T, Dong W-Q, Kuryshev YA, Obejero-Paz CA, Levy MN, Brittenham GM, Kiatchoosakun S, Kirkpatrick D, Hiot BD, Brown AM. 2002. Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med 140:263-271.